Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

a study on High Blood Pressure Interstitial Lung Disease Fibrosis

Summary

for people ages 18 years and up (full criteria)
at Fresno, California and other locations
study started
estimated completion
Vijay Balasubramanian Jeffrey Golden

Description

Summary

This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 314 patients at approximately 120 clinical trial centers. The treatment phase of the study will last approximately 16 weeks. Patients who complete all required assessments will also be eligible to enter an open-label, extension study (RIN-PH-202).

Official Title

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease

Keywords

Pulmonary Hypertension Interstitial Lung Disease Combined Pulmonary Fibrosis and Emphysema Treprostinil PH ILD CPFE 6 Minute Walk Test Hypertension Lung Diseases Hypertension, Pulmonary Pulmonary Fibrosis Emphysema Lung Diseases, Interstitial Inhaled Treprostinil

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Subject voluntarily gives informed consent to participate in the study.
  2. Males and females aged 18 years or older at the time of informed consent.
  3. Females of reproductive potential must be non-pregnant (as confirmed by a urine pregnancy test at screening) and non-lactating, and will: i. Either abstain from intercourse (when it is in line with their preferred and usual lifestyle), or ii. Use two medically acceptable, highly-effective forms of contraception for the duration of study, and at least 30 days after discontinuing study drug.
  4. Males with a partner of childbearing potential must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.
  5. The subject has a confirmed diagnosis of WHO Group 3 PH based on CT imaging, which demonstrates evidence of diffuse parenchymal lung disease performed within 6 months prior to randomization. Subjects may have any form of ILD or CPFE.
  6. Subjects are required to have a right heart catheterization (RHC) within one year prior to randomization with the following documented parameters:
  7. Pulmonary vascular resistance (PVR) > 3 Wood Units (WU) and
  8. A pulmonary capillary wedge pressure (PCWP) of < 15 mmHg and and
  9. A mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg
  10. Baseline 6MWD ≥ 100 meters
  11. Subjects on a chronic medication for underlying lung disease (ie, pirfenidone,nintedanib, etc) must be on a stable and optimized dose for ≥ 30 days prior to randomization. Subjects receiving pirfenidone or nintedanib must have been receiving treatment for at least 90 days and on a stable dose for at least 30 days prior to randomization.
  12. In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing and likely to be cooperative with protocol requirements, including attending all study visits.
  13. Subjects with connective tissue disease (CTD) must have a Baseline FVC of < 70%.

You CAN'T join if...

  1. The subject has a diagnosis of pulmonary arterial hypertension (PAH) or PH for reasons other than WHO Group 3 PH-ILD as outlined in inclusion criterion 3.
  2. The subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.
  3. The subject has received any PAH approved therapy including: prostacyclin therapy(i.e., epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonist (selexipag), endothelin receptor antagonist (ERA), phosphodiesterase type 5 inhibitor (PDE-5I), or soluble guanylate cyclase (sGC) within 60 days of randomization.
  4. The subject has evidence of clinically significant left-sided heart disease as defined by:
  5. PCWP > 15 mmHg
  6. Left ventricular ejection fraction < 40%.

Note: Subjects with abnormal left ventricular function attributable entirely to impaired left ventricular filling due to the effects of right ventricular overload(i.e., right ventricular hypertrophy and/or dilatation) will not be excluded.

  1. The subject is receiving > 10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
  2. Current use of any inhaled tobacco/marijuana products or significant history of drug abuse at the time of informed consent.
  3. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infection within 30 days of randomization.
  4. Initiation of pulmonary rehabilitation within 12 weeks prior to the randomization.
  5. In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or has any disease or condition (ie,peripheral vascular disease, musculoskeletal disorder, morbid obesity) that would likely be the primary limit to ambulation (as opposed to PH).
  6. . Use of any investigational drug/device, or participation in any investigational study with therapeutic intent within 30 days prior to randomization.
  7. . Severe concomitant illness limiting life expectancy (< 6 months).
  8. . Acute pulmonary embolism within 90 days of randomization.

Locations

  • University of California San Francisco - Fresno accepting new patients
    Fresno California 93701 United States
  • University of California San Francisco accepting new patients
    San Francisco California 94143 United States
  • Kaiser Permanente accepting new patients
    San Francisco California 94115 United States

Lead Scientists

  • Vijay Balasubramanian
    Vijay Balasubramanian, M.D. Clinical Professor, UCSF Medical Director of Pulmonary Hypertension-Community Regional Medical Center Vijay Balasubramanian, M.D., specializes in pulmonary disease. He is board certified in Internal Medicine. His residency and fellowship training were completed at the Medical College of Wisconsin.
  • Jeffrey Golden
    Authored (or co-authored) 82 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
United Therapeutics
ID
NCT02630316
Phase
Phase 2/3
Study Type
Interventional
Last Updated